|Mr. Rostislav Raykov||CEO & Director||468.45k||N/A||1976|
|Mr. Robert C. Andrade||Chief Financial Officer||339.41k||N/A||1975|
|Mr. Mark Meier||Sr. VP of Commercial||N/A||N/A||N/A|
|Mr. Mark Gowland||Controller||N/A||N/A||N/A|
|Mr. Lei Fang||Pres of Pharstat Inc||N/A||N/A||N/A|
|Ms. Anne McKay||Regulatory Consultant||N/A||N/A||1954|
|Mr. Alexander D. Smith M.S.||Consultant||N/A||N/A||N/A|
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.’s ISS Governance QualityScore as of December 1, 2022 is 6. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 5; Compensation: 7.